Final set of interim data from PXS-5505 trial in 10 patients treated for 6 months demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity. Read more here. Watch an interview with CEO Gary Phillips here.
Nature communications publishes peer-reviewed data from highly predictive pre clinical models using cells from mylodysplastic syndrome patients. Best in class results from combination of pxs-5505 and standard of care demonstrates a strong rationale for treatment of several blood cancers. Read more here.
Research published in *Nature Cancer* showed Pharmaxis’ pan-LOX inhibitor PXS-5505 increased survival by 35% compared to chemotherapy alone in pancreatic cancer models.
Pharmaxis sold its mannitol respiratory business, including Aridol and Bronchitol, and formed Syntara, a drug development company focused on blood-related cancers.
Syntara announced the first patient was dosed in a Phase 2 study of PXS-4728 for isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) in Parkinson’s disease-risk patients.
targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.